Company intelligence / Profile preview

ETERN Therapeutics

Shanghai, Shanghai Shi, Chinaeterntx.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 1

Overview

ET0038, an allosteric SHP2 inhibitor developed in-house by ETERN, received FDA “STUDY MAY PROCEED” letter in May and NMPA approval in July of 2021. Several other projects are advancing through preclinical candidate screening or preparing for IND submissions[3][6].

Therapeutic areas: Oncology
Modalities: Small molecule drugs targeting protein liquid-liquid phase separation (LLPS)
Industry: Biotech

Drug pipeline

8 assets

ET0038

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ETERN Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETERN Therapeutics.

Explore the full profile